Smith & Nephew PLC - Asset Resilience Ratio
Smith & Nephew PLC (SN) has an Asset Resilience Ratio of -0.69% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check SN capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1985–2023)
This chart shows how Smith & Nephew PLC's Asset Resilience Ratio has changed over time. See SN net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Smith & Nephew PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Smith & Nephew PLC.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX-69.00 Million | -0.69% |
| Total Liquid Assets | GBX-69.00 Million | -0.69% |
Asset Resilience Insights
- Limited Liquidity: Smith & Nephew PLC maintains only -0.69% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Smith & Nephew PLC Industry Peers by Asset Resilience Ratio
Compare Smith & Nephew PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351 |
Medical Devices | 49.23% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236 |
Medical Devices | 25.01% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 9.96% |
|
EBR Systems Inc
AU:EBR |
Medical Devices | 54.70% |
Annual Asset Resilience Ratio for Smith & Nephew PLC (1985–2023)
The table below shows the annual Asset Resilience Ratio data for Smith & Nephew PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | -0.69% | GBX-69.00 Million ≈ $-8.40K |
GBX9.99 Billion ≈ $1.22 Million |
+0.98pp |
| 2021-12-31 | -1.67% | GBX-182.00 Million ≈ $-22.14K |
GBX10.92 Billion ≈ $1.33 Million |
-0.46pp |
| 2020-12-31 | -1.21% | GBX-133.00 Million ≈ $-16.18K |
GBX11.01 Billion ≈ $1.34 Million |
-0.07pp |
| 2019-12-31 | -1.14% | GBX-106.00 Million ≈ $-12.90K |
GBX9.30 Billion ≈ $1.13 Million |
+0.00pp |
| 2018-12-31 | -1.14% | GBX-92.00 Million ≈ $-11.19K |
GBX8.06 Billion ≈ $980.55K |
-0.35pp |
| 2017-12-31 | -0.79% | GBX-62.00 Million ≈ $-7.54K |
GBX7.87 Billion ≈ $957.06K |
-0.80pp |
| 2015-12-31 | 0.01% | GBX1.00 Million ≈ $121.67 |
GBX7.17 Billion ≈ $872.02K |
-2.95pp |
| 2012-12-31 | 2.96% | GBX167.00 Million ≈ $20.32K |
GBX5.64 Billion ≈ $686.47K |
-0.03pp |
| 2011-12-31 | 2.99% | GBX142.00 Million ≈ $17.28K |
GBX4.75 Billion ≈ $577.57K |
+2.68pp |
| 2009-12-31 | 0.31% | GBX14.00 Million ≈ $1.70K |
GBX4.57 Billion ≈ $555.43K |
-4.16pp |
| 2005-12-31 | 4.47% | GBX133.00 Million ≈ $16.18K |
GBX2.98 Billion ≈ $362.09K |
-2.12pp |
| 2004-12-31 | 6.59% | GBX192.27 Million ≈ $23.39K |
GBX2.92 Billion ≈ $355.22K |
-8.84pp |
| 2003-12-31 | 15.43% | GBX342.86 Million ≈ $41.72K |
GBX2.22 Billion ≈ $270.44K |
+15.33pp |
| 1995-12-31 | 0.10% | GBX1.24 Million ≈ $150.41 |
GBX1.27 Billion ≈ $154.82K |
-0.13pp |
| 1994-12-31 | 0.22% | GBX2.97 Million ≈ $361.42 |
GBX1.32 Billion ≈ $160.83K |
0.00pp |
| 1993-12-31 | 0.23% | GBX2.96 Million ≈ $359.95 |
GBX1.31 Billion ≈ $159.01K |
-0.77pp |
| 1991-12-31 | 0.99% | GBX15.72 Million ≈ $1.91K |
GBX1.58 Billion ≈ $192.56K |
-6.44pp |
| 1990-12-31 | 7.43% | GBX114.00 Million ≈ $13.87K |
GBX1.53 Billion ≈ $186.61K |
-1.81pp |
| 1989-12-31 | 9.24% | GBX125.00 Million ≈ $15.21K |
GBX1.35 Billion ≈ $164.62K |
+3.48pp |
| 1988-12-31 | 5.76% | GBX73.34 Million ≈ $8.92K |
GBX1.27 Billion ≈ $154.90K |
-2.86pp |
| 1987-12-31 | 8.62% | GBX105.86 Million ≈ $12.88K |
GBX1.23 Billion ≈ $149.34K |
+2.47pp |
| 1986-12-31 | 6.16% | GBX54.70 Million ≈ $6.66K |
GBX888.50 Million ≈ $108.10K |
-2.22pp |
| 1985-12-31 | 8.37% | GBX53.88 Million ≈ $6.56K |
GBX643.40 Million ≈ $78.28K |
-- |
About Smith & Nephew PLC
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; t… Read more